← Oncology Approval Tracker

FDA DECISION ·

Zynyz

retifanlimab-dlwr · Incyte

Accelerated approvalNew therapyMerkel cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Dec 17, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

For adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

LAMPGEN ANALYSIS

Why it matters

The accelerated approval added a PD-1 inhibitor for an uncommon skin cancer.

What research teams should watch

Verify pathology and disease extent, and follow the confirmatory program for the exact indication.

PRIMARY RECORDS

Sources